Skip to main content

Table 3 Correlation of CDK4 pathway aberrations to clinicopathologic features of mucosal melanoma

From: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Clinicopathologic factor CDK4 aberration CCND1 aberration
Gain Normal P value Gain Loss Normal P value
Age (year)    0.552     0.853
Median (range) 56.5 ± 11.6 54.9 ± 11.3   56.4 ± 11.3 55.3 ± 11.6 55.4 ± 11.6  
Gender n (%)    0.409     0.413
 Male 41 (41.0) 39 (35.5)   20 (33.9) 18 (47.4) 45 (38.8)  
 Female 59 (59.0) 71 (64.5)   39 (66.1) 20 (52.6) 71 (61.2)  
Ulceration n (%)    0.555     0.769
 Yes 52 (52.0) 49 (44.5)   25 (42.4) 20 (52.6) 58 (50.0)  
 No 20 (20.0) 26 (23.6)   14 (23.7) 9 (23.7) 23 (19.8)  
 NA 28 (28.0) 35 (31.8)   20 (33.9) 9 (23.7) 35 (30.2)  
Depth of invasion    0.981     0.853
 T1 ≤ 1 mm 13 (13.0) 16 (14.5)   10 (16.9) 4 (10.5) 15 (12.9)  
 T2 1–2 mm 21 (21.0) 24 (21.8)   10 (16.9) 11 (28.9) 25 (21.6)  
 T3 2–4 mm 18 (18.0) 20 (18.2)   10 (16.9) 6 (15.8) 22 (19.0)  
 T4 > 4 mm 48 (48.0) 50 (45.5)   29 (49.2) 17 (44.7) 54 (46.6)  
Anatomic site n (%)    0.153     0.885
 Head and neck 51 (51.0) 41 (37.3)   27 (45.8) 15 (39.5) 52 (44.8)  
 Oesophagus 8 (8.0) 11 (10.0)   3 (5.1) 5 (13.2) 11 (9.5)  
 Anorectum 21 (21.0) 23 (20.9)   13 (22.0) 9 (23.7) 23 (19.8)  
 Genitourinary 20 (20.0) 35 (31.8)   16 (27.1) 9 (23.7) 30 (25.9)  
Stages n (%)    0.004     0.239
 I 5 (5.0) 1 (0.9)   0 (0.0) 1 (2.6) 5 (4.3)  
 II 46 (46.0) 67 (60.9)   30 (50.8) 26 (68.4) 58 (50.0)  
 III 38 (38.0) 22 (20.0)   18 (30.5) 9 (23.7) 34 (29.3)  
 IV 11 (11.0) 20 (18.0)   11 (18.6) 2 (5.3) 19 (16.4)  
Survival (months)    0.054     0.702
 Median (95% CI) 45.0 (39.3, 50.7) 41.2 (35.4, 47.0)   43 (40.2, 45.8) 47.4 (38.9, 55.9) 45.0 (40.0, 50.0)  
 Median follow-up time (95% CI) 38.1 (26.0, 50.2) 37.0 (25.5, 48.5) 0.322 44.5 (27.4, 61.6) 39.5 (22.2, 56.8) 31.0 (18.3, 43.7) 0.453
Clinicopathologic factor P16INK4a aberration Overall aberration (≥ 1 CNV)
Loss Normal P value Yes No P value
Age (year)    0.733    0.581
Median (range) 55.4 ± 11.5 56.2 ± 11.4   55.5 ± 11.4 56.3 ± 12.0  
Gender n (%)    0.903    0.771
 Male 48 (39.0) 34 (38.2)   67 (38.5) 16 (41.0)  
 Female 75 (61.0) 55 (61.8)   107 (61.5) 23 (59.0)  
Ulceration n (%)    0.014    0.189
 Yes 52 (42.3) 51 (57.3)   81 (46.6) 22 (56.4)  
 No 25 (20.3) 21 (23.6)   36 (20.7) 10 (25.6)  
 NA 46 (37.4) 17 (119.1)   36 (20.7) 7 (17.9)  
Depth of invasion    0.053    0.348
 T1 ≤ 1 mm 20 (16.3) 9 (10.1)   26 (14.9) 3 (7.7)  
 T2 1–2 mm 33 (26.8) 13 (14.6)   40 (23.0) 6 (15.4)  
 T3 2–4 mm 19 (15.4) 19 (21.3)   29 (16.7) 9 (23.1)  
 T4 > 4 mm 51 (41.5) 48 (53.9)   79 (45.4) 21 (53.8)  
Anatomic site n (%)    0.379    0.691
 Head and neck 55 (44.7) 39 (43.8)   79 (45.4) 15 (38.5)  
 Oesophagus 14 (11.4) 5 (5.6)   16 (9.2) 3 (7.7)  
 Anorectum 22 (17.9) 22 (24.7)   34 (19.5) 11 (28.2)  
 Genitourinary 32 (26.0) 23 (25.8)   45 (25.9) 10 (25.6)  
Stages n (%)    0.515    
 I 4 (3.3) 2 (2.2)   5 (2.9) 1 (2.6) 0.059
 II 65 (52.8) 49 (55.1)   90 (51.7) 24 (61.5)  
 III 39 (31.7) 22 (24.7)   56 (32.2) 5 (12.8)  
 IV 15 (12.2) 16 (18.0)   23 (13.2) 9 (23.1)  
Survival (months)    0.528    0.169
 Median (95% CI) 43.6 (40.0, 47.2) 43.6 (32.3, 54.9)   44.0 (40.4, 47.6) 43.6 (18.6, 68.6)  
 Median follow-up time (95% CI) 39.7 (29.7, 49.7) 33.7 (22.3, 45.1) 0.137 38.1 (31.7, 44.5) 21.9 (17.8, 26.0) 0.206
Clinicopathologic factor CDK4 gain + CCND1 gain CDK4 gain + P16INK4a loss
Positive Negative P value Positive Negative P value
Age (year)    0.866    0.722
Median (range) 57.6 ± 11.1 55.4 ± 11.5   56.2 ± 11.1 55.5 ± 11.6  
Gender n (%)    0.817    0.382
 Male 12 (40.0) 68 (37.8)   28 (42.4) 52 (36.1)  
 Female 18 (60.0) 112 (62.2)   38 (57.6) 92 (63.9)  
Ulceration n (%)    0.690    0.971
 Yes 13 (43.3) 88 (48.9)   31 (47.0) 70 (48.6)  
 No 6 (20.0) 40 (22.2)   15 (22.7) 31 (21.5)  
 NA 11 (36.7) 52 (28.9)   20 (30.3) 43 (29.9)  
Depth of invasion    0.767    0.527
 T1 ≤ 1 mm 3 (10.0) 26 (14.4)   8 (12.1) 21 (14.6)  
 T2 1–2 mm 5 (16.7) 40 (22.2)   18 (27.3) 27 (18.8)  
 T3 2–4 mm 6 (20.0) 32 (17.8)   10 (15.2) 28 (19.4)  
 T4 > 4 mm 16 (53.3) 82 (45.6)   30 (45.5) 68 (47.2)  
Anatomic site n (%)    0.160    0.935
 Head and neck 16 (53.3) 76 (42.2)   31 (47.0) 61 (42.4)  
 Oesophagus 3 (10.0) 16 (8.9)   6 (9.1) 13 (9.0)  
 Anorectum 8 (26.7) 36 (20.0)   13 (19.7) 31 (21.5)  
 Genitourinary 3 (10.0) 52 (28.9)   16 (24.2) 39 (27.1)  
Stages n (%)    0.213    0.088
 I 0 (0.0) 6 (3.3)   4 (6.1) 2 (1.4)  
 II 12 (40.0) 101 (56.1)   32 (48.5) 81 (56.2)  
 III 12 (40.0) 48 (26.7)   23 (34.8) 37 (25.7)  
 IV 6 (20.0) 25 (13.9)   7 (10.6) 24 (16.7)  
Survival (months)    0.757    0.174
 Median (95% CI) 44.0 (41.4, 46.6) 43.6 (39.3, 47.9)   44.0 (41.4, 46.6) 43.0 (37.6, 48.4)  
 Median follow-up time (95% CI) 54.0 (29.2, 78.8) 37.0 (30.0, 44.0) 0.636 38.1 (25.9, 50.3) 37.0 (29.1, 44.9) 0.153
Clinicopathologic factor P16INK4a loss + CCND1 gain CDK4 gain + P16INK4a loss + CCND1 gain
Positive Negative P value Positive Negative P value
Age (year)    0.531    0.807
Median (range) 58.1 ± 12.5 55.3 ± 11.2   59.2 ± 12.8 55.3 ± 11.4  
Gender n (%)    0.927    0.476
 Male 13 (39.4) 69 (38.5)   8 (47.1) 75 (38.3)  
 Female 20 (60.6) 110 (61.5)   9 (52.9) 121 (61.7)  
Ulceration n (%)    0.220    0.857
 Yes 13 (39.4) 90 (50.3)   8 (47.1) 95 (48.5)  
 No 6 (18.2) 40 (22.3)   3 (17.6) 43 (21.9)  
 NA 14 (42.4) 49 (27.4)   6 (35.3) 58 (29.6)  
Depth of invasion    0.584    0.682
 T1 ≤ 1 mm 7 (21.2) 22 (12.3)   1 (5.9) 28 (14.3)  
 T2 1–2 mm 7 (21.1) 39 (21.8)   3 (17.6) 43 (21.9)  
 T3 2–4 mm 5 (15.2) 33 (18.4)   3 (17.6) 35 (17.9)  
 T4 > 4 mm 14 (42.4) 85 (47.5)   10 (58.8) 90 (45.9)  
Anatomic site n (%)    0.404    0.497
 Head and neck 18 (54.5) 76 (42.5)   9 (52.9.6) 85 (43.4)  
 Oesophagus 1 (3.0) 18 (10.0)   1 (5.9) 18 (9.2)  
 Anorectum 6 (18.2) 38 (21.1)   5 (29.4) 40 (20.4)  
 Genitourinary 8 (24.2) 47 (26.1)   2 (11.8) 53 (27.0)  
Stages n (%)    0.383    0.268
 I 0 (0.0) 6 (3.4)   0 (0.0) 6 (3.1)  
 II 16 (48.5) 98 (54.7)   6 (35.3) 108 (55.1)  
 III 13 (39.4) 48 (26.8)   8 (47.1) 53 (27.0)  
 IV 4 (12.1) 27 (15.1)   3 (17.6) 29 (14.8)  
Survival (months)    0.287    0.145
 Median (95% CI) 42 (35.0, 49.0) 45.5 (40.8, 50.2)   42 (33.5, 50.5) 45 (40.5, 49.4)  
 Median follow-up time (95% CI) 55.5 (20.3, 90.7) 35.0 (27.6, 42.4) 0.102 38.1 (25.9, 50.3) 37.0 (29.1, 44.9) 0.153